The firm is developing the immunotherapy IMNN-001 for treating ovarian cancer and assessing its efficacy in patients with homologous recombination deficiency.
Below is a list of the 10 precision oncology stories that resonated most with readers during the year: 2. Mass General Brigham Becomes Latest US Health System to Adopt Pretreatment DPYD Testing 3. JP ...
The firm is betting that adding the G-quadruplex stabilizer to the ADC will improve outcomes in HER2-low breast cancer patients.
The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.
Stories about federal funding cuts, lab test regulation, and increasing adoption of DPYD testing were the most popular among readers.
NEW YORK – Royalty Pharma has acquired the remaining royalty interest of PTC Therapeutics in Roche's spinal muscular atrophy drug Evrysdi (risdiplam) for up to $300 million, the company announced ...
The NDA is supported by data from a single-arm, multi-center, open-label, Phase II registration study in China that completed enrollment of 87 patients in March.
Patients submitted for consideration for treatment with GS010/Lumevoq must meet specific eligibility criteria, including the length of time since the onset of their vision loss.
Endometrial02, researchers want to see whether Enhertu can replace current standard-of-care chemotherapy for patients with HER2-expressing tumors.
NEW YORK – BioMarin has stopped developing the investigational BMN 349 for treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease, the company announced in a regulatory filing this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback